PALISADE BIO INC
For the period ended Mar 27, 2024. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 27, 2024 · Filed Mar 27, 2024
PALI$1.13-2.6%Stored close · as of Nov 6, 2026
Contents
EX-99.01 · PALI-2108 Development Program
PALI-2108 Development Program
The Company continues to advance its lead program, PALI-2108, for the treatment of moderate-to-severe ulcerative colitis (UC) toward a Phase 1 clinical study. PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.